AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Repetitive Transcranial Magnetic Stimulation and Postoperative Neurocognitive Recovery

RecruitingNAAges 65 Years - anyAllPeking University First Hospital
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Patients with preoperative cognitive impairment are at increased risks of delayed neurocognitive recovery (DNR) and postoperative neurocognitive disorder (POCD). Repetitive transcranial magnetic stimulation (rTMS) has been used to improve cognitive function in patients with cognitive impairement. This trial is designed to compare the effects of rTMS versus sham intervention on postoperative neurocognitive function in patients with preoperative cognitive impairment.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Aged โ‰ฅ65 years; 2. Patients with preoperative mild to moderate cognitive impairment, defined as 9\<Montreal Cognitive Assessment (MoCA)\<26; 3. Scheduled for elective non-cardiac surgery under general anesthesia, with an expected surgical duration of \>2 hours; 4. Expected to stay in hospital for at least 5 days after surgery. Exclusion Criteria: 1. Left-handed; 2. Primary school education level or below; 3. Comorbid diseases including mental illness, intellectual disability, auditory and visual dysfunction, language impairment, severe neurological disorders, or other diseases that impede the completion of evaluation; 4. Neurosurgery; 5. Presence of contraindications to rTMS treatment, including epilepsy, pregnant or lactating women, or with a metal or electric implanted device (e.g., deep brain stimulator, ventriculoperitoneal shunt, aneurysm clip, pacemaker, cochlear implant, or surgical staples on the scalp); 6. Other situations that are deemed unsuitable for inclusion in the study.
๐Ÿ’Š

What it tests

  • Repetitive transcranial magnetic stimulation
  • Sham stimulation
๐Ÿ“

Where

3 sites
Peking University First Hospital
Beijing, China
Peking University Shenzhen Hospital
Shenzhen, China
Xijing Hospital, Air Force Medical University
Xi'an, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy